Bruix J, Sherman M, American Association for the Study of Liver, D (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022. https://doi.org/10.1002/hep.24199

Article  PubMed  Google Scholar 

Chen Y, Lei Y, Lin J, Huang Y, Zhang J, Chen K, Sun S, Lin X (2020) The LINC01260 functions as a tumor suppressor via the miR-562/CYLD/NF-kappaB Pathway in non-small cell lung cancer. Onco Targets Ther 13:10707–10719. https://doi.org/10.2147/OTT.S253730

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D (2021) Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res 149:1–61. https://doi.org/10.1016/bs.acr.2020.10.001

Article  CAS  PubMed  Google Scholar 

Drake KM, Ruteshouser EC, Natrajan R, Harbor P, Wegert J, Gessler M, Pritchard-Jones K, Grundy P, Dome J, Huff V, Jones C, Aldred MA (2009) Loss of heterozygosity at 2q37 in sporadic Wilms’ tumor: putative role for miR-562. Clin Cancer Res 15(19):5985–5992. https://doi.org/10.1158/1078-0432.CCR-09-1065

Article  CAS  PubMed  PubMed Central  Google Scholar 

Farazi PA, DePinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6(9):674–687. https://doi.org/10.1038/nrc1934

Article  CAS  PubMed  Google Scholar 

Furth N, Aylon Y (2017) The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway. Cell Death Differ 24(9):1488–1501. https://doi.org/10.1038/cdd.2017.99

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han LL, Yin XR, Zhang SQ (2018) miR-103 promotes the metastasis and EMT of hepatocellular carcinoma by directly inhibiting LATS2. Int J Oncol 53(6):2433–2444. https://doi.org/10.3892/ijo.2018.4580

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang XY, Huang ZL, Xu YH, Zheng Q, Chen Z, Song W, Zhou J, Tang ZY, Huang XY (2017) Comprehensive circular RNA profiling reveals the regulatory role of the circRNA-100338/miR-141-3p pathway in hepatitis B-related hepatocellular carcinoma. Sci Rep 7(1):5428. https://doi.org/10.1038/s41598-017-05432-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Josson S, Gururajan M, Sung SY, Hu P, Shao C, Zhau HE, Liu C, Lichterman J, Duan P, Li Q, Rogatko A, Posadas EM, Haga CL, Chung LW (2015) Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis. Oncogene 34(21):2690–2699. https://doi.org/10.1038/onc.2014.212

Article  CAS  PubMed  Google Scholar 

Lee Y, Kim NH, Cho ES, Yang JH, Cha YH, Kang HE, Yun JS, Cho SB, Lee SH, Paclikova P, Radaszkiewicz TW, Bryja V, Kang CG, Yuk YS, Cha SY, Kim SY, Kim HS, Yook JI (2018) Dishevelled has a YAP nuclear export function in a tumor suppressor context-dependent manner. Nat Commun 9(1):2301. https://doi.org/10.1038/s41467-018-04757-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li SP, Xu HX, Yu Y, He JD, Wang Z, Xu YJ, Wang CY, Zhang HM, Zhang RX, Zhang JJ, Yao Z, Shen ZY (2016) LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway. Oncotarget 7(27):42431–42446. https://doi.org/10.18632/oncotarget.9883

Article  PubMed  PubMed Central  Google Scholar 

Lin Y, Peng S, Yu H, Teng H, Cui M (2012) RNAi-mediated downregulation of NOB1 suppresses the growth and colony-formation ability of human ovarian cancer cells. Med Oncol 29(1):311–317. https://doi.org/10.1007/s12032-010-9808-5

Article  CAS  PubMed  Google Scholar 

Liu YC, Yeh CT, Lin KH (2020) Cancer stem cell functions in hepatocellular carcinoma and comprehensive therapeutic strategies. Cells. https://doi.org/10.3390/cells9061331

Article  PubMed  PubMed Central  Google Scholar 

Loh C-Y, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP, Looi CYJC (2019) The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. Cells 8(10):1118

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mittal V (2018) Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol 13:395–412. https://doi.org/10.1146/annurev-pathol-020117-043854

Article  CAS  PubMed  Google Scholar 

Parasramka MA, Maji S, Matsuda A, Yan IK, Patel T (2016) Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma. Pharmacol Ther 161:67–78. https://doi.org/10.1016/j.pharmthera.2016.03.004

Article  CAS  PubMed  PubMed Central  Google Scholar 

Powell EE, Wong VW, Rinella M (2021) Non-alcoholic fatty liver disease. Lancet 397(10290):2212–2224. https://doi.org/10.1016/S0140-6736(20)32511-3

Article  CAS  PubMed  Google Scholar 

Rusnak L, Tang C, Qi Q, Mo X, Fu H (2018) Large tumor suppressor 2, LATS2, activates JNK in a kinase-independent mechanism through ASK1. J Mol Cell Biol 10(6):549–558. https://doi.org/10.1093/jmcb/mjy061

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH (2019) An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J Cell Physiol 234(5):5451–5465. https://doi.org/10.1002/jcp.27486

Article  CAS  PubMed  Google Scholar 

Su Y, Lv X, Yin W, Zhou L, Hu Y, Zhou A, Qi F (2019) CircRNA Cdr1as functions as a competitive endogenous RNA to promote hepatocellular carcinoma progression. Aging (albany NY) 11(19):8183–8203. https://doi.org/10.18632/aging.102312

Article  PubMed  Google Scholar 

Tan Y, Ouyang H, Xiao X, Zhong J, Dong M (2019) Irisin ameliorates septic cardiomyopathy via inhibiting DRP1-related mitochondrial fission and normalizing the JNK-LATS2 signaling pathway. Cell Stress Chaperones 24(3):595–608. https://doi.org/10.1007/s12192-019-00992-2

Article  PubMed  PubMed Central  Google Scholar 

Tian Y, Lv W, Lu C, Zhao X, Zhang C, Song H (2019) LATS2 promotes cardiomyocyte H9C2 cells apoptosis via the Prx3-Mfn2-mitophagy pathways. J Recept Signal Transduct Res 39(5–6):470–478. https://doi.org/10.1080/10799893.2019.1701031

Article  CAS  PubMed  Google Scholar 

Wong CM, Tsang FH, Ng IO (2018) Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. Nat Rev Gastroenterol Hepatol 15(3):137–151. https://doi.org/10.1038/nrgastro.2017.169

Article  CAS  PubMed  Google Scholar 

Wu Y, Zhang Y, Qin X, Geng H, Zuo D, Zhao Q (2020) PI3K/AKT/mTOR pathway-related long non-coding RNAs: roles and mechanisms in hepatocellular carcinoma. Pharmacol Res 160:105195. https://doi.org/10.1016/j.phrs.2020.105195

Article  CAS  PubMed  Google Scholar 

Xie Y, Lv Y, Zhang Y, Liang Z, Han L, Xie Y (2019) LATS2 promotes apoptosis in non-small cell lung cancer A549 cells via triggering Mff-dependent mitochondrial fission and activating the JNK signaling pathway. Biomed Pharmacother 109:679–689. https://doi.org/10.1016/j.biopha.2018.10.097

Article  CAS  PubMed  Google Scholar 

Xie C, Li SY, Fang JH, Zhu Y, Yang JE (2021) Functional long non-coding RNAs in hepatocellular carcinoma. Cancer Lett 500:281–291. https://doi.org/10.1016/j.canlet.2020.10.042

Article  CAS  PubMed  Google Scholar 

Xin T, Lv W, Liu D, Jing Y, Hu F (2020) ROCK1 knockdown inhibits non-small-cell lung cancer progression by activating the LATS2-JNK signaling pathway. Aging (albany NY) 12(12):12160–12174. https://doi.org/10.18632/aging.103386

Article  CAS  PubMed  Google Scholar 

Xu J, Ji L, Liang Y, Wan Z, Zheng W, Song X, Gorshkov K, Sun Q, Lin H, Zheng X, Chen J, Jin RA, Liang X, Cai X (2020) CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal Transduct Target Ther 5(1):298. https://doi.org/10.1038/s41392-020-00375-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang Y, Chen L, Gu J, Zhang H, Yuan J, Lian Q, Lv G, Wang S, Wu Y, Yang YT, Wang D, Liu Y, Tang J, Luo G, Li Y, Hu L, Sun X, Wang D, Guo M, Xi Q, Xi J, Wang H, Zhang MQ, Lu ZJ (2017) Recurrently deregulated lncRNAs in hepatocellular carcinoma. Nat Commun 8:14421. https://doi.org/10.1038/ncomms14421

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang L, Zhang C, Bai X, Xiao C, Dang E, Wang G (2020) hsa_circ_0003738 inhibits the suppressive function of tregs by targeting miR-562/IL-17A and miR-490-5p/IFN-gamma signaling pathway. Mol Ther Nucleic Acids 21:1111–1119. https://doi.org/10.1016/j.omtn.2020.08.001

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ye J, Li TS, Xu G, Zhao YM, Zhang NP, Fan J, Wu J (2017) JCAD Promotes progression of nonalcoholic steatohepatitis to liver cancer by inhibiting LATS2 kinase activity. Cancer Res 77(19):5287–5300. https://doi.org/10.1158/0008-5472.CAN-17-0229

Article  CAS  PubMed